Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | LDHB | P07195 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6966557 | 0.81 | RAB9A (0.42) | NPC1RAB9AALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL183194 | 0.81 | RAB9A (0.42) | NPC1RAB9ACYP3A4ALDH1A1MAPK1 | |
| SCHEMBL6650651 | 0.79 | POLB (0.50) | NPC1RAB9AALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL2866739 | 0.79 | CYP1A2 (0.42) | NPC1RAB9ANOTUMCYP3A4ACHE | |
| SCHEMBL473470 | 0.79 | KDM4E (0.46) | NOTUMALDH1A1LDHAMAPTHPGD | |
| SCHEMBL7321755 | 0.79 | RAB9A (0.41) | NPC1RAB9AALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL8930012 | 0.79 | RAB9A (0.41) | NPC1RAB9AALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL19769133 | 0.77 | FFAR1 (0.42) | NPC1RAB9ACYP3A4ALDH1A1MAPK1 | |
| SCHEMBL11696604 | 0.77 | ALDH1A1 (0.42) | NPC1RAB9ANOTUMCYP3A4ACHE | |
| SCHEMBL10846303 | 0.76 | ALDH1A1 (0.48) | NPC1RAB9ACYP3A4ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108383828-A | 1 new, 2- as chemokine receptor modulators is bis--sulfamide derivative | 阿勒根公司 | 2018-08-10 | — | — | CN | claimed |
| EP-2955173-B1 | 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-10-04 | — | — | EP | claimed |
| US-9603834-B2 | 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-03-28 | — | — | US | claimed |
| US-20160228407-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2016-08-11 | — | — | US | claimed |
| EP-2955173-A1 | NOVEL 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2015-12-16 | — | — | EP | claimed |
| EP-2651901-B1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2015-05-27 | — | — | EP | claimed |
| US-20140221351-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | claimed |
| US-20140051682-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-02-20 | — | — | US | claimed |
| CN-103384662-A | Novel 1, 2-bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN INC | 2013-11-06 | — | — | CN | claimed |
| EP-2651901-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-23 | — | — | EP | claimed |
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | claimed |
| WO-2012082633-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | claimed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | claimed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | claimed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | claimed |
| CN-1444481-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | CN | claimed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | claimed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-3950171-A | THERMOPLASTIC RESIN DIAZONIUM SALT | MITA INDUSTRIAL CO. LTD. (JA) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228407-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | NPC1 2440/4885RAB9A 1158/4885NOTUM 4390/4885 |
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | NPC1 1211/4885RAB9A 1322/4885NOTUM 2808/4885 |
| US-20140051682-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | NPC1 2440/4885RAB9A 1158/4885NOTUM 4390/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | NPC1 1557/4885RAB9A 2214/4885NOTUM 3302/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | NPC1 1211/4885RAB9A 1322/4885NOTUM 2808/4885 |
| US-20140221351-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | NPC1 2440/4885RAB9A 1158/4885NOTUM 4390/4885 |
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | NPC1 2440/4885RAB9A 1158/4885NOTUM 4390/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | NPC1 1211/4885RAB9A 1322/4885NOTUM 2808/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | NPC1 1211/4885RAB9A 1322/4885NOTUM 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.